Onyx Pharmaceuticals Inc: Highlights
Financial data in U.S. dollars
| Financial Highlights |
|---|
| Sales |
232.72 Mil |
| Income |
-8.52 Mil |
| Net Profit Margin |
-3.66% |
| Return on Equity |
-1.37% |
| Debt/Equity Ratio |
0.19 |
|
| Revenue/Share |
4.02 |
| Earnings/Share |
-0.16 |
| Book Value/Share |
12.05 |
| Dividend Rate |
0.00 |
| Payout Ratio |
0.00% |
|
| Revenue - Quarterly Results (in Millions) |
|---|
| | FY (12/09) | FY (12/08) | FY (12/07) |
|---|
| 1st Qtr | 53.7 | 48.9 | 0.0 |
| 2nd Qtr | 60.2 | 45.1 | 0.0 |
| 3rd Qtr | 69.1 | 50.8 | 0.0 |
| 4th Qtr | NA | 49.7 | 26.1 |
| Total | 183.1 | 194.3 | 26.1 |
| Earnings Per Share - Quarterly Results |
|---|
| | FY (12/09) | FY (12/08) | FY (12/07) |
|---|
| 1st Qtr | $0.07 | $0.28 | -$0.26 |
| 2nd Qtr | $0.16 | $0.08 | -$0.22 |
| 3rd Qtr | $0.14 | $0.22 | $0.01 |
| 4th Qtr | NA | -$0.53 | -$0.21 |
| Total | $0.37 | $0.05 | -$0.68 |
| Qtr. over Qtr. EPS Growth Rate |
| FY (12/09) | FY (12/08) | FY (12/07) |
|---|
| 1st Qtr | NA | NA | --- |
| 2nd Qtr | 129% | -71% | 15% |
| 3rd Qtr | -12% | 175% | NA |
| 4th Qtr | NA | NA | NA |
| Yr. over Yr. EPS Growth Rate |
| FY (12/09) | FY (12/08) |
|---|
| 1st Qtr | -75% | NA |
| 2nd Qtr | 100% | NA |
| 3rd Qtr | -36% | 2,100% |
| 4th Qtr | NA | -152% |
advertisement
Recent News